In this episode of Divergent States, 3L1T3 sits down with Betty Aldworth, the new co-president of MAPS, as she steps into shared leadership with Ismail Ali following Rick Doblin’s four-decade run. Betty brings decades of experience in drug policy reform, from Colorado’s 2012 cannabis legalization campaign to leading Students for Sensible Drug Policy, and now helps guide MAPS through one of the movement’s most pivotal moments: the FDA’s rejection of Lycos Therapeutics’ MDMA-assisted therapy ap...
All content for Divergent States is the property of Divergent States and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this episode of Divergent States, 3L1T3 sits down with Betty Aldworth, the new co-president of MAPS, as she steps into shared leadership with Ismail Ali following Rick Doblin’s four-decade run. Betty brings decades of experience in drug policy reform, from Colorado’s 2012 cannabis legalization campaign to leading Students for Sensible Drug Policy, and now helps guide MAPS through one of the movement’s most pivotal moments: the FDA’s rejection of Lycos Therapeutics’ MDMA-assisted therapy ap...
Tom Feegel: Can Psychedelics Heal the Opioid Crisis?
Divergent States
1 hour
6 months ago
Tom Feegel: Can Psychedelics Heal the Opioid Crisis?
In this powerful new episode of Divergent States, your hosts 3L1T3 and Bryan sit down with Tom Feegel—CEO and Co-Founder of Beond, a pioneering Ibogaine clinic based in Mexico, to discuss the unfiltered realities of healing, addiction recovery, and the evolving landscape of psychedelic-assisted therapy. Tom brings two decades of sobriety, a past life in global brand marketing, and deep experience navigating both the light and shadow of the psychedelic resurgence. This isn’t a conversation fu...
Divergent States
In this episode of Divergent States, 3L1T3 sits down with Betty Aldworth, the new co-president of MAPS, as she steps into shared leadership with Ismail Ali following Rick Doblin’s four-decade run. Betty brings decades of experience in drug policy reform, from Colorado’s 2012 cannabis legalization campaign to leading Students for Sensible Drug Policy, and now helps guide MAPS through one of the movement’s most pivotal moments: the FDA’s rejection of Lycos Therapeutics’ MDMA-assisted therapy ap...
